Human T-cell lymphotropic virus type 1 exposures following blood-borne virus incidents in Central Australia, 2002-2012

Clinical Infectious Diseases

Volumn 59, Issue 1, 2014, Pages 85-87

  Hewagama, S ^a   Krishnaswamy, S ^a   King, L ^a   Davis, J ^b   Baird, R ^c  

^a ALICE SPRINGS HOSPITAL   (Australia)

^b MENZIES SCHOOL OF HEALTH RESEARCH   (Australia)

^c ROYAL DARWIN HOSPITAL   (Australia)

Author keywords

HTLV 1; needlestick; occupational exposure

Indexed keywords

LAMIVUDINE PLUS ZIDOVUDINE;

ANTIVIRAL THERAPY; ARTICLE; AUSTRALIA; EXPOSURE; FOLLOW UP; HUMAN; HUMAN T CELL LEUKEMIA VIRUS 1; HUMAN T CELL LEUKEMIA VIRUS INFECTION; MAJOR CLINICAL STUDY; MEDICAL AUDIT; OCCUPATIONAL EXPOSURE; POST EXPOSURE PROPHYLAXIS; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK ASSESSMENT; BLOODBORNE BACTERIUM; COMPLICATION; HEALTH CARE PERSONNEL; HTLV-I INFECTIONS; HUMAN T-LYMPHOTROPIC VIRUS 1; ISOLATION AND PURIFICATION; NEEDLESTICK INJURY; PROCEDURES; TRANSMISSION;

AUSTRALIA; BLOOD-BORNE PATHOGENS; HEALTH PERSONNEL; HTLV-I INFECTIONS; HUMAN T-LYMPHOTROPIC VIRUS 1; HUMANS; NEEDLESTICK INJURIES; OCCUPATIONAL EXPOSURE; POST-EXPOSURE PROPHYLAXIS;

EID: 84904015390     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/ciu227     Document Type: Article

References (12)

1. Goncalves DU, Proietti FA, Ribas JG, et al. Epidemiology, treatment, and prevention of human T-cell leukemia virus type 1-associated diseases. Clin Microbiol Rev 2010; 23:577-89.
2. Osame M, Janssen R, Kubota H, et al. Nationwide survey of HTLVI-associated myelopathy in Japan: association with blood transfusion. Ann Neurol 1990; 28:50-6.
3. Khabbaz RF, Onorato IM, Cannon RO, et al. Seroprevalence of HTLV-1 and HTLV-2 among intravenous drug users and persons in clinics for sexually transmitted diseases. N Engl J Med 1992; 326:375-80.
4. Bastian I, Hinuma Y, Doherty RR. HTLV-I among Northern Territory aborigines. Med J Aust 1993; 159:12-6.
5. Einsiedel L, Fernandes L, Spelman T, Steinfort D, Gotuzzo E. Bronchiectasis is associated with human T-lymphotropic virus 1 infection in an Indigenous Australian population. Clin Infect Dis 2012; 54:43-50.
6. Goubau P, Carton H, Cornet P, et al. Human T-cell lymphotropic virus type 1 infection and tropical spastic paraparesis in Belgian expatriates. J Med Virol 1992; 36:13-5.
7. Yamaguchi K, Mochizuki M, Watanabe T, et al. Human T lymphotropic virus type 1 uveitis after Graves' disease. Br J Ophthalmol 1994; 78: 163-6.
8. Hill SA, Lloyd PA, McDonald S, Wykoff J, Derse D. Susceptibility of human T cell leukemia virus type I to nucleoside reverse transcriptase inhibitors. J Infect Dis 2003; 188:424-7.
9. Trevino A, Parra P, Bar-Magen T, Garrido C, de Mendoza C, Soriano V. Antiviral effect of raltegravir on HTLV-1 carriers. J Antimicrob Chemother 2012; 67:218-21.
10. Kaplan JE, Khabbaz RF, Murphy EL, et al. Male-to-female transmission of human T-cell lymphotropic virus types I and II: association with viral load. The Retrovirus Epidemiology Donor Study Group. J Acquir Immune Defic Syndr Hum Retrovirol 1996; 12:193-201.
11. Manns A, Miley WJ, Wilks RJ, et al. Quantitative proviral DNA and antibody levels in the natural history of HTLV-I infection. J Infect Dis 1999; 180:1487-93.
12. Kuhar DT, Henderson DK, Struble KA, et al. Updated US Public Health Service guidelines for the management of occupational exposures to human immunodeficiency virus and recommendations for postexposure prophylaxis. Infect Control Hosp Epidemiol 2013; 34:875-92.